Uncover more ultralow signals

Uncover more ultralow signals

Discover up to 24% more HER2 ultralow signals, including those previously categorized as HER2-negative.
Improve scoring agreement

Improve scoring agreement

Enhance reading consistency and improve accuracy with objective, reliable HER2 analysis.
Enhance productivity

Enhance productivity

Gain efficiency by shortening reading time for HER2 IHC scoring.

Enhance HER2 IHC Scoring with AI Analysis

Lunit SCOPE HER2 boosts efficiency in HER2 biomarker testing with easy-to-use AI software that improves accuracy, increases speed, and enhances sensitivity—including HER2 ultralow expression often missed in manual review.

Click to See the Publication
Enhance HER2 IHC Scoring with AI Analysis

Proven AI-Powered HER2 Insights

Comparison of original tissue slides and AI-generated heatmaps showing HER2 expression. Highlights AI detection of HER2 ultra-low signals that were previously scored as negative by pathologists.

Uncover more HER2 ultralow signals with AI

A retrospective study shows that among WSIs initially scored as HER2 negative by pathologists, AI-powered analysis identified 23.6% as HER2 ultra-low.
View Clinical Evidence
Bar graph showing pathologist concordance rates increasing from 58.2% to 78.6% with AI-assisted HER2 analysis, indicating a 20% improvement in scoring agreement.

Improve scoring agreement

Enhance reading consistency and improve accuracy with objective, reliable HER2 analysis. A published study shows concordance of pathologists reading improved by 20% after revisiting with AI.
View Clinical Evidence

AI Pathology Software Built to Drive Biopharma Innovation

Our digital image analysis software helps biopharma companies scale oncology R&D, advance biomarker strategies, and optimize trials. Lunit is built for end-to-end CDx development, with mature regulatory capabilities, broad scanner and file type compatibility, and scalable deployment across digital pathology platforms and CRO partners.
How We Help Biopharma

Featured News & Publications

Stay informed with the latest research, product updates, and global partnerships driving innovation in AI-powered precision oncology.

See All News & Publications
Media Hub

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

Media Hub

Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials

Publication

Leveraging artificial intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: Translational analyses of AtezoTRIBE and AVETRIC trials

Related Solutions

Lunit SCOPE PD-L1

Streamline PD-L1 TPS scoring with AI-driven quantification.

Explore Lunit SCOPE PD-L1

For Research Use Only. Not for use in diagnostic procedures or decisions.

Lunit SCOPE uIHC

Accelerate IHC-based biomarker development and enrich clinical trials.

See Lunit SCOPE uIHC

For Research Use Only. Not for use in diagnostic procedures or decisions.

Lunit SCOPE IO

Unlock TME insights with AI-powered immune phenotyping.

View Lunit SCOPE IO

For Research Use Only. Not for use in diagnostic procedures or decisions.

Lunit SCOPE GP

Extract AI-powered genotype prediction for screening and discovery.

See Lunit SCOPE GP

For Research Use Only. Not for use in diagnostic procedures or decisions
Breakthrough Insights to Drive Success in Drug Development

Breakthrough Insights to Drive Success in Drug Development

Equip your team with HER2 quantification software that enhances reading consistency and scoring agreement, and improves workflow efficiency and accuracy.
Contact Us

Frequently Asked Questions

What differentiates Lunit as a partner in AI-powered image analysis?

Our deep expertise, robust clinical evidence, and partnerships with many CROs and digital pathology platform providers set us apart. We prioritize collaboration and offer versatile solutions that are compatible with a wide range of scanners and IMS.